CN100372570C - Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor - Google Patents
Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor Download PDFInfo
- Publication number
- CN100372570C CN100372570C CNB028163176A CN02816317A CN100372570C CN 100372570 C CN100372570 C CN 100372570C CN B028163176 A CNB028163176 A CN B028163176A CN 02816317 A CN02816317 A CN 02816317A CN 100372570 C CN100372570 C CN 100372570C
- Authority
- CN
- China
- Prior art keywords
- glycyl
- carboxyl
- polysaccharide
- glycine
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
A pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of a malignant tumor, which comprises as the active ingredient a polysaccharide derivative comprising a polysaccharide having a carboxyl group bound to an active substance having an anti-tumor activity via an amino acid or a peptide consisting of 2 to 8 amino acids which are the same or different, or a salt thereof.
Description
Technical field
The present invention relates to be used to suppress to shift or prevent the pharmaceutical composition of malignant tumor recurrence.More specifically, the present invention relates to suppress to shift or prevent the pharmaceutical composition of malignant tumor recurrence, said composition comprises polysaccharide derivates or its salt as active component, this polysaccharide derivates comprises having by aminoacid or peptide and the active substance with anti-tumor activity, for example polysaccharide of following formula (I) or the bonded carboxyl of camptothecin derivative (II) is made up of 2-8 identical or different aminoacid.
Background technology
In developed country malignant tumor be cause a dead main diseases because of, and the death of most of malignant tumor pertinence is owing to transferring to the recurrence of following to distant metastasis of human behind organ at a distance or the topical therapeutic.Shift and to bring out to distant metastasis of human by hematogenous metastasis or lymph originality, and there is the high-risk property of malignant tumor recurrence in the known patient who suffers from the transfer of lymph originality behind topical therapeutic.The major organs of recurrence is brain, lung, liver and bone.Especially, the tumor in the digestive organs, the colon cancer that for example a large amount of patients suffer from often can invade and be diffused in the liver, and breast carcinoma and pulmonary carcinoma are also often invaded and propagated in the liver.In addition, lymphoma and lymphoid leukemia can mainly be diffused into lymphsystem, and find to the liver high speed transfer by obduction according to reports
In order to stop recurrence, comprise that to distant metastasis of human (for example shifting to liver) and prolongation life, chemotherapy etc. are used as the maintenance nursing behind the topical therapeutic, but chemotherapeutic toxicity is strong and can't be used for long term administration.In addition, can not report that almost the maintenance nursing that claims the employing chemotherapy prolongs life than independent topical therapeutic more of a specified durationly.For example, carry out in the test of postoperative chemotherapy patient the surgical object that becomes a kind of digestive organs cancer-late gastric cancer, attempted the clinical trial of multiple anti-malignant tumor medicine, but still can't set up than independent operation and have the more Therapeutic Method of good survival rate.
In these cases, wish to find effectively to suppress to recur or prolong the novel drugs of life behind topical therapeutic, it is applicable to the distant place organ of lymph node and transfer and has low side effect, and is fit to long-time administration.
On the other hand, WO 94/19376, and WO 97/46260, and WO 97/38727, and JP-A-10-72467 and JP-A-10-95802 disclose a kind of polysaccharide derivates, and it contains the bonded polysaccharide of active substance by aminoacid or peptide and anti-tumor activity.
Yet, these publications disclose these polysaccharide in treatment of cancer by accumulating at tumor sites and the purposes of kill tumor cell, but never pointed out to suppress to shift or the activity of prevention malignant tumor recurrence.
Summary of the invention
One object of the present invention is to provide a kind of new pharmaceutical composition that is used to suppress to shift or prevent the malignant tumor recurrence.
The inventor has carried out big quantity research, and find to comprise the polysaccharide derivates that has by aminoacid or peptide and the polysaccharide of the bonded carboxyl of active substance that possesses anti-tumor activity suppress to shift and/or the recurrence of prevention malignant tumor in show the effect of excellence, thereby finished the present invention.That is to say, the present invention relates to a kind of pharmaceutical composition that shifts or suppress to shift or prevent the malignant tumor recurrence, it contains polysaccharide derivates or its salt as active component, and this polysaccharide derivates comprises and has peptide of forming by aminoacid or by 2-8 identical or different aminoacid and the polysaccharide with bonded carboxyl of active substance of anti-tumor activity.
The accompanying drawing summary
Fig. 1 represents the quantity of surviving animals in natural law after tumor is implanted and the M 5076 liver metastasis models.
Realize the best mode of invention
Polysaccharide with carboxyl of the present invention comprises that those are disclosed in the homopolysaccharide mutually among above-mentioned WO 94/19376 and the WO97/46260, and be included in its structure have carboxyl originally polysaccharide (for example, hyaluronic acid, pectic acid, alginic acid, chrondroitin, heparin etc.) and originally the polysaccharide that does not have carboxyl but introduce carboxyl (for example, amylopectin, glucosan, mannan, chitin, manna glucosan (mannoglucan), chitosan etc.) do not have carboxyl originally and in its structure but form the polysaccharide (the polysaccharide polyhydric alcohol that for example, has carboxyl) that carboxyl is introduced in the back at polyhydric alcohol.
Originally the polysaccharide that does not have carboxyl but introduce carboxyl is meant that the hydrogen atom of part or all of hydroxyl of the polysaccharide that does not have carboxyl originally is by by carboxyl-C
1-4Alkyl replaces the polysaccharide of making.
In the present invention, the polysaccharide with a polysaccharide comprises by handling the polysaccharide that does not have carboxyl originally with Reducing agent, and with the hydrogen atom of the part or all of hydroxyl of afterproduct by carboxyl-C
1-4Alkyl replaces the polysaccharide of making.
Polysaccharide polyhydric alcohol with carboxyl comprises, for example, and carboxyl-C
1-4Alkyl-polysaccharide polyhydric alcohol, it is to obtain the polysaccharide polyhydric alcohol according to WO 97/46260 described method by handling the polysaccharide that does not have carboxyl originally with sodium metaperiodate and sodium borohydride successively, it further uses halo C
1-4Alkyl carboxylic acid is handled and is made.
Carboxyl-the C that replaces the hydroxyl hydrogen atom of above-mentioned polysaccharide (comprising the polysaccharide polyhydric alcohol)
1-4The moieties of alkyl can be straight chained alkyl or branched alkyl.
Preferred carboxyl-C
1-4Alkyl is, for example, and carboxymethyl, 1-carboxymethyl, 3-carboxylic propyl group, 1-methyl-3-carboxylic propyl group, 2-methyl-3-carboxylic propyl group, 4-carboxylic butyl etc. and more preferably carboxymethyl.
In the present invention, the preferred carboxyl-C of polysaccharide that has carboxyl
1-4Alkyl glucosan or carboxyl-C
1-4Alkyl glucosan polyhydric alcohol and especially preferred carboxyl-C
1-4Glucosan.
At above-mentioned preparation carboxyl-C
1-4The degree that polyhydric alcohol forms in the step of alkyl-polysaccharide polyhydric alcohol (successively by with sodium periodate oxidation and use sodium borohydride reduction) does not have concrete regulation, but intermediate polysaccharide polyhydric alcohol preferably obtain by processing polysaccharide under the possible condition that almost completely forms polyhydric alcohol basically those.
In addition, in the present invention, polysaccharide with carboxyl is carboxymethyl dextran resin or carboxymethyl dextran resin polyhydric alcohol preferably, and in these polysaccharide, particularly more preferably have 20,000-500, the glucosan of 000 mean molecule quantity, and most preferably have 50,000-350, (described mean molecule quantity is to measure Shinseikagaku by gel permeation chromatography (GPC) method to the glucosan of 000 mean molecule quantity, Jikken Koza, vol.20, p.7, Tokyo-Kagaku-Dojin, November5,1991).
When introducing carboxyalkyl in polysaccharide, the table of degree of its introducing is shown ＂ substitution value ＂, and it is (group that comprises the peptide chain that these groups are introduced) determined by the carboxyalkyl number of each saccharide residue.It is with following formulate.
When carboxyl was carboxymethyl, the degree of replacement was expressed as carboxymethylated degree (CM-degree) sometimes.
When polysaccharide is a glucosan, its substitution value is preferably in the scope of 0.3-0.8.When polysaccharide was the glucosan polyhydric alcohol, its substitution value was preferably in the scope of 0.3-0.5.
Aminoacid of the present invention or peptide are at the polysaccharide with carboxyl and have the performance effect of base at interval between the active substance of anti-tumor activity, and the aminoacid of aminoacid and the described peptide of formation comprises that natural amino acid and synthesizing amino acid (comprise D-aminoacid, L-amino, and comprise neutral amino acid, basic amino acid or acidic amino acid its mixture).In addition, aminoacid of the present invention not only can be a-amino acid, but also can be beta-amino acids, gamma-amino acid, epsilon-amino acid etc.
Amino acid whose example is a glycine, α-Bing Ansuan, alanine, valine, leucine, isoleucine, serine, threonine, systeine, methionine, aspartic acid, glutamic acid, lysine, citrulline, arginine, phenylalanine, tyrosine, histidine, tryptophan, proline, hydroxyproline, γ-An Jidingsuan, episilon amino caproic acid etc.
Peptide of the present invention comprises by an identical or different 2-8 aminoacid, preferred 2-5 peptide that aminoacid is formed.The example of described peptide is glycyl-glycyl-L-or D-phenylalanyl-glycine; glycyl-glycine; glycyl-glycyl-glycine; glycyl-glycyl-glycyl-glycine; glycyl-glycyl-glycyl-glycyl-glycine; L-or D-phenylalanyl-glycine; L-or D-tyrosyl--glycine; L-or D-leucyl--glycine, L-or D-phenylalanyl-citrulline and L-or D-be valyl-citrulline (the N-end of these peptides is incorporated on the carboxyl of polysaccharide).
In these peptides; preferred glycyl-glycyl-L-or D-phenylalanyl-glycine; glycyl-glycine; glycyl-glycyl-glycine; glycyl-glycyl-glycyl-glycine; glycyl-glycyl-glycyl-glycyl glycine and L-or D-phenylalanyl-glycine.
Active substance with anti-tumor activity of the present invention can comprise the multiple chemical compound that is called antineoplastic agent, and can be cytotoxic drug or cytostatic agent.Preferred camptothecin derivative of cytotoxic drug and Taxane derivative, and the preferred angiogenesis inhibitor of cytostatic agent, the EGF acceptor inhibitor.More preferably, cytotoxic drug is a camptothecin derivative, and cell to press down the growth preparation be angiogenesis inhibitor.
The example of camptothecin derivative is the chemical compound that is disclosed in the formula (I) among the JP-A-10-72467:
R wherein
1Be that replace or unsubstituted low alkyl group, X
1Be the group of following formula :-NHR
2(R
2Be hydrogen atom or low alkyl group) and Alk be the optional straight or branched C that contains oxygen atom in its chain
1-6Alkylidene.Wherein, preferred chemical compound is 10-(3 '-amino propoxyl group)-7-ethyl-(20S)-camptothecine.
Other examples of camptothecin derivative are the chemical compounds that are disclosed in following formula among the JP-A-10-95802 (II):
R wherein
2-R
6In two groups adjacent one another are in conjunction with forming low-grade alkylidene, and a carbon atom of described low-grade alkylidene replaced by amino, and R
2-R
6Its excess-three group be hydrogen atom, low alkyl group or halogen atom.
Wherein, preferred chemical compound be (1S, 9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H, 12H-benzo [de] pyrans also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-10,13 (9H, 15H)-diketone etc.
The example of Taxane derivative is paclitaxel, Taxotere, 13-[(2 ' R, 3 ' R)-3 ' N-tert-butoxycarbonyl-3 '-cyclopropyl]-10-deacetylation-Baccatine III etc.
In active component of the present invention, polysaccharide can be selected according to the kind of the polysaccharide that uses with the ratio of the active substance with anti-tumor activity, but when polysaccharide is glucosan or glucosan polyhydric alcohol, the content of active substance that then has anti-tumor activity is preferably in the scope of 0.1-20% (weight), more preferably in the scope of 2-10% (weight), based on the gross weight meter of active component.
In active component of the present invention, preferred polysaccharide derivant or its salt, wherein aminoacid or the peptide is made up of 2-8 identical or different aminoacid are incorporated into by amido link in the part or all of carboxyl of the polysaccharide with carboxyl, and remainder or all less than the bonded amino of carboxyl of participation and above-mentioned peptide or carboxyl passes through amido link or ester bond combines with carboxyl, amino or the hydroxyl of the active substance with anti-tumor activity.
Especially preferred active component is a polysaccharide derivates; the polysaccharide that wherein has carboxyl is a carboxymethyl dextran resin; active substance with anti-tumor activity is 10-(3 '-amino propoxyl group)-7-ethyl-(20S)-camptothecine; and described peptide is glycyl-glycyl-glycine, or its salt.Especially preferred is polysaccharide derivates or its salt, and the polysaccharide that wherein has carboxyl is that mean molecule quantity is 60,000-200,000 and its carboxymethylated degree carboxymethyl dextran resin that is 0.3-0.8.
Other preferred active component are polysaccharide derivates, and the polysaccharide that wherein has carboxyl is carboxyl-C
1-4Alkyl glucosan polyhydric alcohol; active substance with anti-tumor activity is (1S; 9S)-1-amino-9-ethyl-5-fluoro-2; 3-dihydro-9-hydroxy-4-methyl-1H; 12H-benzo [de] pyrans also [3 '; 4 ': 6,7] indolizino [1,2-b] quinoline-10; 13 (9H; 15H)-diketone and described peptide are glycyl-glycyl-L-or D-phenylalanyl-glycine, or its salt; with especially preferred be polysaccharide derivates or its salt; the polysaccharide that wherein has carboxyl is that mean molecule quantity is 200,000-400,000 and its substitution value be carboxyl-C in the 0.3-0.5 scope
1-4Alkyl glucosan polyhydric alcohol.
The polysaccharide derivates of active component of the present invention or its salt can be according to WO 94/19376.WO97/46260, and WO 97/38727, JP-A-10-72467 and the preparation of JP-A-10-95802 disclosed method.
Pharmaceutical composition of the present invention can highly be accumulated in for example lymph node that cancer can be spread to or the position of liver, can make this active substance be difficult to act on normal cell but inhibition acts on the growth of tumor cell with suitable speed release of active agent, therefore pharmaceutical composition of the present invention effectively suppresses to shift or prevent the recurrence of malignant tumor.Particularly, pharmaceutical composition of the present invention effectively suppresses lymphatic metastasis and liver shifts, and particularly effectively suppresses lymphatic metastasis.And in lymphatic metastasis, pharmaceutical composition of the present invention effectively suppresses to be shifted in lymph node by colon, or is shifted in lymph node by lung.
In addition, pharmaceutical composition of the present invention can be not only before shifting beginning, but also can after shifting beginning, bring into play its effect.So, the recurrence (for example, operation, radiotherapy, thermotherapy, cryotherapy, laser calcination therapy etc.) of malignant tumor after pharmaceutical composition of the present invention also effectively suppresses transfer or prevents topical therapeutic.In addition, pharmaceutical composition of the present invention also is fit to long repetitively administered, and can unite use with local treatment.
Pharmaceutical composition of the present invention is preferably through parenterai administration (for example, intravenous administration), and usually with the form administration of liquid preparation, for example solution, suspensoid, Emulsion etc.
The suitable form that is formulated as injection or instillation with distilled water for injection, normal saline solution, D/W of pharmaceutical composition of the present invention.
The dosage of pharmaceutical composition of the present invention can be according to changes such as medication, patient's age, body weight or situations, but general single dose is in the scope of 0.002-50mg/kg, and more preferably in the scope of 0.01-5mg/kg, to calculate be the amount of active substance to change.
In description of the present invention, low alkyl group and low-grade alkylidene can be to have 1-6 carbon atom, those of preferred 1-4 carbon atom, and described halogen atom is fluorine atom, chlorine atom, bromine atoms, iodine atom etc.
Test
Test 1 (M5076 liver metastasis model)
M5076 cell with 100 ten thousand (mouse ovarian sarcoma cell) is implanted in the tail vein of BDF1 male mice (5-week age, 8 animal/groups).With test compounds (compd A; Chemical compound that following preparation 1 obtains and Irinotecan (CPT-11)) be dissolved in the normal saline solution, and the 4th, 8 and 12 day intravenous gives each consumption shown in the mice following table 1 after implantation, and 120 days observation mices behind the implantation tumour.In matched group (not handling), only give normal saline solution with test compounds.Time-to-live in mensuration test compounds processed group and the matched group (my god), and calculate the rate elongation of survival according to following formula.Result such as table 1 and shown in Figure 1.
Rate elongation=(natural law-1 of surviving in the natural law/matched group of surviving in test compounds-processed group) * 100 of survival
Table 1
| Dosage (mg/kg) | The survival natural law | Standard deviation | The rate elongation (%) of survival | |
| Contrast | 15.00 | 1.24 | - | |
| Compd A | 12.5 | 37.57 | 5.27 | 50.5 |
| 25 | 43.13 | 5.98 | 187.5 | |
| 50 | 48.71 | 5.33 | 224.8 | |
| Irinotecan | 80 | 22.50 | 0.5 | 50.0 |
As shown in table 1, below the effect that in M5076 liver metastasis model, shows good prolongation life of the chemical compound (compd A) that obtains of preparation example 1.Simultaneously, it is the medicine that suppresses to shift or prevent the malignant tumor recurrence that Irinotecan can't be considered, but only tests as the medicine of camptothecin derivative.
Test 2 (HT-29 metastasis models)
With section (2mm
2) HT-29 cell (human colon carcinoma) be implanted in the anthelmintic sample vermiform appendix of 100NCr nu/nu female mice (5-6 week age, 10 animal/groups).Test compounds (compd A; The chemical compound that following preparation example 1 obtains, compd B; The chemical compound that following preparation example 4 obtains, and Irinotechan (CPT-11)) be dissolved in the normal saline solution, and the 15th, 19,23 and 25 day intravenous gives each consumption shown in the mice following table 2 behind implantation tumour.On the other hand, in matched group (not handling), only give normal saline solution with test compounds.Behind implantation tumour, checked whether each organ exists metastasis on the 84th day.The result is as shown in table 2.
Table 2
| Group | Number of animals | Lymph node | Liver | Lung | Other organ *** | There is the number of animals that shifts | |||||
| MI * | P ** | MI * | P ** | MI * | P ** | MI * | P ** | P ** | |||
| Compd A (40mg/kg) **** | 10 | 0 | <0.01 | 0 | 1.0 | 0 | 0.21 | 0 | 1.0 | 0 | <0.01 |
| Compd A (20mg/kg) **** | 10 | 1 | <0.01 | 0 | 1.0 | 1 | 0.58 | 0 | 1.0 | 2 | <0.01 |
| Compd A (10mg/kg) **** | 10 | 8 | 1.0 | 0 | 1.0 | 2 | 1.0 | 0 | 1.0 | 8 | 1.0 |
| Compd A (5mg/kg) **** | 10 | 6 | 0.3 | 0 | 1.0 | 1 | 0.58 | 2 | 1.0 | 6 | 0.30 |
| Compd B (5mg/kg) **** | 10 | 0 | <0.01 | 0 | 1.0 | 0 | 0.21 | 0 | 1.0 | 0 | <0.01 |
| Compd B (2.5mg/kg) **** | 10 | 6 | 0.30 | 1 | 1.0 | 1 | 0.58 | 1 | 1.0 | 6 | 0.3 |
| Irinotecan(40mg/kg) | 10 | 7 | 0.58 | 0 | 1.0 | 1 | 0.58 | 1 | 1.0 | 7 | 0.58 |
| Irinotecan(20mg/kg) | 10 | 9 | 1.0 | 2 | 1.0 | 2 | 1.0 | 0 | 1.0 | 9 | 1.0 |
| Contrast | 10 | 9 | - | 1 | - | 3 | - | 1 | - | 9 | - |
*: MI is meant the transfer incidence rate
*: P is meant standard deviation, and wherein all processed group are utilized Fishcer accurately test and matched group contrast.
* *: comprise barrier film, abdominal cavity and thoracic cavity.
* * *: the dosage that is converted into 10-(3 '-amino propoxyl group)-7-ethyl-(20S)-camptothecine
* * * *: be converted into (1S, 9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H, 12H-benzo [de] pyrans also [3 ', 4 ': 6,7] indolizino [1,2-b] and quinoline-10,13 (9H, 15H)-dosetest 3 (HT-29 metastasis model) of diketone
With one section (2mm
2) HT-29 cell (human colon carcinoma) be implanted to the wriggling sample vermiform appendix of 100NCr nu/nu female mice (5-6 week age, 10 animal/groups).Observed lymphatic metastasis on the 49th day behind the implantation tumour, with test compounds (compd A; The chemical compound that following preparation example 1 obtains, and Irinotechan (CPT-11)) be dissolved in the normal saline solution, and the 51st, 55,59 and 63 day intravenous gives the mice following table 3 described each consumptions behind implantation tumour.On the other hand, in matched group (not handling), only give normal saline solution with test compounds.Behind implantation tumour, checked whether each organ exists metastasis on the 84th day.The result is as shown in table 3 below.
Table 3
| Group | Number of animals | Lymph node | Liver | Lung | Other organ *** | There is the number of animals that shifts | |||||
| MI * | P ** | MI * | P ** | MI * | P ** | MI * | P ** | P ** | |||
| Compd A (40mg/kg) **** | 10 | 0 | <0.01 | 0 | 1.0 | 0 | 0.21 | 2 | 1.0 | 2 | <0.01 |
| Compd A (20mg/kg) **** | 10 | 2 | <0.01 | 0 | 1.0 | 0 | 0.21 | 1 | 1.0 | 3 | <0.01 |
| Irinotecan(40mg/kg) | 10 | 8 | 1.0 | 1 | 1.0 | 0 | 0.21 | 1 | 1.0 | 8 | 1.0 |
| Contrast | 10 | 9 | - | 1 | - | 3 | - | 1 | - | 9 | - |
*: MI is meant the transfer incidence rate
*: P is meant standard deviation, and wherein all processed group are utilized Fishcer accurately test and matched group contrast.
* *: comprise barrier film, abdominal cavity and thoracic cavity.
* * *: the dosage that is converted into 10-(3 '-amino propoxyl group)-7-ethyl-(20S)-camptothecine
Test 4 (H460 metastasis models)
With one section (2mm
2) H460 cell (people's pulmonary carcinoma) be implanted to the left lung of 100NCr nu/nu female mice (5-6 week age, 10 animal/groups).Shift from observation in the 14th day behind another matched group implantation tumour, with test compounds (compd A; The chemical compound that following preparation example 1 obtains, compd B; The chemical compound that following preparation example 4 obtains, Compound C; And Irinotechan (CPT-11)) be dissolved in the normal saline solution, and the 14th, 18,22 and 26 day intravenous gives the mice following table 4 described each consumptions behind implantation tumour.On the other hand, in matched group (not handling), only give normal saline solution with test compounds.Behind implantation tumour, checked whether each organ exists metastasis on the 36th day.The result is as shown in table 4 below.
Table 4
| Group | Number of animals | Lymph node | Liver | Lung | There is the number of animals that shifts | ||||
| MI * | P ** | MI * | P ** | MI * | P ** | P ** | |||
| Compd A (40mg/kg) **** | 10 | 1 | <0.01 | 0 | 1.0 | 0 | 0.54 | 1 | <0.01 |
| Compd A (20mg/kg) **** | 10 | 2 | 0.05 | 0 | 1.0 | 2 | 0.58 | 3 | 0.245 |
| | compd A (10mg/kg) **** | 10 | 1 | <0.01 | 0 | 1.0 | 0 | 0.54 | 1 | 0.02 |
| Compd A (5mg/kg) **** | 10 | 2 | 0.05 | 0 | 1.0 | 1 | 1.0 | 2 | 0.06 |
| Compd B (5mg/kg) **** | 10 | 2 | 0.05 | 0 | 1.0 | 1 | 1.0 | 2 | 0.06 |
| Compd B (2.5mg/kg) **** | 10 | 1 | <0.01 | 0 | 1.0 | 0 | 0.54 | 1 | 0.02 |
| Irinotecan(40mg/kg) | 10 | 0 | <0.01 | 0 | 1.0 | 1 | 1.0 | 1 | 0.02 |
| Irinotecan(80mg/kg) | 10 | 2 | 0.05 | 0 | 1.0 | 0 | 0.54 | 2 | 0.06 |
| |
20 | 13 | - | 0 | - | 2 | - | 12 | - |
*: MI is meant the transfer incidence rate
*: P is meant standard deviation, and wherein all processed group are utilized Fishcer accurately test and matched group contrast.
* *: comprise barrier film, abdominal cavity and thoracic cavity.
* * *: the dosage that is converted into 10-(3 '-amino propoxyl group)-7-ethyl-(20S)-camptothecine
* * * *: be converted into (1S, 9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H, 12H-benzo [de] pyrans also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-10,13 (9H, 15H)-dosage of diketone
Preparation example
Preparation example 1
CM-glucosan-7-ethyl-10-[3 '-(glycyl-glycyl-glycyl amino) propoxyl group]-(20S)-camptothecine:
(the CM-glucosan is meant Sensor Chip CM 5, and is hereinafter identical)
(1) 10-(3 '-amino propoxyl group)-7-ethyl-(20S)-camptothecine hydrochlorate (500mg) is dissolved in the acetonitrile (25ml); and to wherein adding tert-butoxycarbonyl glycyl-glycyl-glycine (345mg), N-methylmorpholine (121mg), N-hydroxybenzotriazole (161mg) and 1-(3-dimethylamino-propyl group)-3-ethyl-carbodiimide hydrochloride (228mg) successively and this mixture stirring being spent the night.By filtering the product of collecting precipitation; obtain light yellow cystose powder by silica gel chromatography; it obtains 7-ethyl-10-[3 '-(tert-butoxycarbonyl-glycyl-glycyl-glycyl amino) propoxyl group by the normal propyl alcohol recrystallization]-(20S)-and camptothecine (663mg), it is a colourless crystallization.
M.p.：157-159℃。
(2) 7-ethyl-10-[3 '-(tert-butoxycarbonyl-glycyl-glycyl-glycyl amino) propoxyl group]-(20S)-camptothecine (3.86g) emulsifying in pure water (64ml); and to wherein adding 6N aqueous hydrochloric acid solution (32ml), and with stirring reaction under this mixture room temperature 2 hours.Concentrated solvent, and be settled out powdered product to wherein adding normal propyl alcohol.Collect the gained powdered product by filtering, and obtain 7-ethyl-10-[3 '-(glycyl-glycyl-glycyl amino) propoxyl group by moisture normal propyl alcohol recrystallization]-(20S)-and camptothecine hydrochlorate (2.56g), it is a yellow crystal.
(3) CM-glucosan sodium salt (CM-degree=0.44; 50g) be dissolved in the water (2.5 liters); and its pH value with the 0.2N aqueous hydrochloric acid solution stir and 15 ℃ be adjusted downward to pH 5.0, and to wherein adding 7-ethyl-10-[3 '-(glycyl-glycyl-glycyl amino) propoxyl group]-(20S)-camptothecine hydrochlorate (4.01g).Add 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (50g) to this mixture, the pH value of reaction solution remains on 5.0-5.5 with 0.2N hydrochloric acid in this process.This mixture 15 ℃ and stir under reaction 1 hour, and be diluted to the cumulative volume of 10L with pure water.When pH value remains on about pH4.0, utilize ultrafiltration module (ACP-1010, Asahi KaseiIndustries, Ltd. make) remove and hang down the molecule fraction, and its pH value transfers to pH8 with the 0.1N sodium hydrate aqueous solution, and carry out ion exchange resin MSC-1 (Na-type, Dowex makes) subsequently.Concentrate the fraction that contains required compound, and filter through filter (0.45 μ m).Gains mix with ethanol (10L) and stir, to wherein under agitation dripping 3M saline (40ml).Collect the precipitation that obtains by filtering, and be dissolved in the pure water (21L).The pH value of this solution transfers to pH4.0 with the 0.2N aqueous hydrochloric acid solution, and carries out ultrafiltration at this, and pH value remains on pH4.0 during this period.The cumulative volume of concentrated solvent to 1.5 liter, and filter through filter (0.45 μ m).Gains mix with ethanol (9 liters), and to wherein under agitation dripping 3M saline (35ml).Collect the gained precipitation by filtering, and use ethanol and washing with acetone successively, decompression concentrates down and obtains required compound (54.9g), and it is a buff powder.Content as 10-(3 '-amino propoxyl group)-7-ethyl-(20S)-camptothecine hydrochlorate turns out to be 4.2% by the absorbance under 367.5nm.Analyze by GPC (gel permeation chromatography), the mean molecule quantity of required product is 121kDa, and the degree (Mw/Mn) that distributes is 1.47.
Preparation example 2
CM-glucosan-13-[(2 ' R, 3 ' S)-3 '-N-tert-butoxycarbonyl-3 '-phenyl-2 '-O-L-phenylalanyl-glycyl-different seryl-]-preparation of 10-deacylated tRNA base-Baccatine III:
(Bz is a benzoyl, and is after this identical)
With CM-glucosan (2008mg; CM-degree: 0.47; mean molecule quantity: 170kDa) under agitation be dissolved in pure water (90ml); and to wherein adding 13-[(2 ' R; 3 ' S)-3 '-N-tert-butoxycarbonyl-3 '-phenyl-2 '-O-L-phenylalanyl-glycyl-different seryl-]-10-deacylated tRNA base-Baccatine III methylsulfonyl salt (119mg) and dimethyl formamide (90ml), and stir this mixture to dissolving.Stir and to this mixture add 2-ethyoxyl-1-(2H)-quinolinecarboxylic acid (4.0g) down, and at room temperature stir this mixture overnight.Under agitation in this reaction solution, add ethanol (720ml), and under agitation to wherein further dripping 3M saline (1.8ml).By centrifugal collecting precipitation, and be dissolved in the water (200ml), and the pH value of this solution transferred to pH7 with the 0.2N sodium hydrate aqueous solution.With this solution impouring ethanol (800ml) under agitation, and under agitation to wherein dripping 3M saline (4ml).By the precipitation of centrifugal collection gained, and obtain required compound (600mg), as white powder according to the identical mode purification of preparation example 1-(3).
Content of active substance: 2.4% (the UV method, (λ=276nm))
Preparation example 3
CM-glucosan-2 '-preparation of O-phenylalanyl-glycyl-paclitaxel:
CM-glucosan (1.294g; CM-degree: 0.47; mean molecule quantity: 170 kDa) under agitation be dissolved in the pure water (70ml); and to wherein add 2 '-O-phenyl-alanyl-glycyl paclitaxel mesylate (77mg) and dimethyl formamide (70ml) and this mixture further stirred so that dissolving.Stir down 2-ethyoxyl-1 (2H)-quinolinecarboxylic acid (2.59g) is joined in this mixture, and this mixture reaction is stirred simultaneously spend the night.Under stirring this reaction solution is joined ethanol (700ml), and under agitation to wherein dripping 3M saline (1.4ml).By centrifugal collecting precipitation, and water-soluble (240ml), stir down and mix with ethanol (1200ml).Stir down and in this mixture, drip 3M saline (4.8ml) so that precipitation.In the same manner, further repeat 3 precipitations and obtain required product (746mg), it is a white powder.
Content of active substance: 4.8% (the UV method (=273nm))
Preparation example 4
Sensor Chip CM 5-polyhydric alcohol-(1S; 9S)-(glycyl-glycyl-L-phenylalanyl-glycyl amino)-9-ethyl-5-fluoro-2; 3-dihydro-9-hydroxy-4-methyl-1H; 12H-benzo [de] pyrans also [3 '; 4 ': 6,7] indolizino [1,2-b] quinoline-10; 13 (9H; 15H)-diketone: (1) (1S, 9S)-1-(tert-butoxycarbonyl-glycyl-glycyl-L-phenylalanyl-glycyl amino)-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H; 12H-benzo [de] pyrans [3 '; 4 ': 6,7] indolizino [1,2-b] quinoline-10; 13 (9H, 15H)-diketone:
To (1S, 9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H, 12H-benzo [de] pyrans also-[3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-10,13 (9H, 15H)-dione hydrochloride (167mg; 0.354mmol), tert-butoxycarbonyl glycyl-glycyl-L-phenylalanyl-glycine (463mg; 1.06mmol) and I-hydroxybenzotriazole monohydrate (HOBT) (143mg; 1.06mmol) in the solution of dimethyl formamide (DMF) in (10ml), add 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide (EDC) hydrochlorate (270mg; 1.42mmol), triethylamine (148 μ 1; 1.06mmol) and 4-dimethylaminopyridine (DMAP) (5mg; 0.04mmol).Stirred this reactant mixture 15 hours under the room temperature, and concentrated solvent under the decompression.Residue is dissolved in the chloroform, and washs this mixture, and drying and decompression be evaporating solvent down.Residue is by silica gel chromatography (solvent; Chloroform: methanol=50: 1-10: (228mg, yield: 75%), it is a light yellow solid 1) to obtain title compound.
IR(Nujol)；3290，1710，1655cm
-1
ESI-MS；854(M+H)
(2) (1S; 9S)-1-(glycyl-glycyl-L-phenyl-propionamido-glycyl amino)-9-ethyl-5-fluoro-2; 3-dihydro-9-hydroxy-4-methyl-1H; 12H-benzo [de] pyrans also [3 '; 4 ': 6,7] indolizino [1,2-b] quinoline-10; 13 (9H, 15H)-preparation of diketone:
Stir in ice bath to (1S, 9S)-1-(tert-butoxycarbonyl-glycyl-glycyl-L-phenylalanyl-glycyl amino)-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H, 12H-benzo [de] pyrans also-[3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-10,13 (9H, 15H)-diketone (220mg; 0.258mmol add 4N hydrogen chloride De dioxane solution (6ml) in the solution in the) Zai diox (4ml).Stirred this mixture 16 hours under the room temperature.In reactant mixture, add ether (30ml), and this mixture stirred at room temperature 1 hour.By the filtration collecting precipitation, and drying obtains title compound (176mg, yield; 86%), it is a yellow powder.
IR(Nujol)；3250，1745，1660，1605，1535cm
-1
ESI-MS；754(M+H)
(3) preparation of glucosan polyhydric alcohol (PA-glucosan):
(0.1M, pH5.5 1000ml) place three neck round-bottomed flask (capacity with acetate buffer; 3 liters).Under the room temperature glucosan T-500 (10.0g, Amersham Pharmacia Biotech AB makes) gradation in 30 minutes is joined above-mentioned buffer.With this mixture stir about 30 minutes until this solution becomes clarification, after this, cooling this mixture to 5 ℃ (interior temperature) in bathing outside.
Independently, to flask (capacity; 1 liter) add sodium metaperiodate (33.0g) and water (1000ml), and stir this mixture under the room temperature, after this 5 ℃ of coolings down.
Stir and 5 ℃ under add above-mentioned sodium periodate solution to above-mentioned dextran solution, and with 5 ℃ of maintenances in this mixture dark place 5 days.Remove excessive sodium metaperiodate by adding ethylene glycol (10ml), to wherein adding the 8M sodium hydrate aqueous solution, during reaction temperature keep below 6 ℃ (pH value of reactant mixture changes) about pH9.Stir gradation down to this reactant mixture adding sodium borohydride (14g), this mixture is stirred down at 5 ℃ spend the night.In order to remove excessive sodium borohydride, the pH value of this reactant mixture transfers to by adding acetic acid under 3-6 ℃ and is lower than pH5.5, and this mixture was further stirred 2 hours.The pH value of this reactant mixture transfers to about pH7.8 with the 8M sodium hydroxide solution.The relative water of this mixture (Spectora that dialyses
/ Por 3 films, weight shutoff＜3500), and lyophilization obtains glucosan polyhydric alcohol (8.34g), and it is an amorphous powder.
(4) preparation of Sensor Chip CM 5 polyhydric alcohol (CM-PA-glucosan):
Water (155ml) is placed three neck round-bottomed flask (capacity; 500ml), in 10 minutes, also stir under the room temperature to wherein adding glucosan polyhydric alcohol (5.18g).Stir and became clarification until this mixture in the about 10-30 of this mixture minute, after this stir gradation down with sodium hydroxide (sheet, 97.0%, 21.8g) join the glucosan polyhydric alcohol solutions, during warm at 30-40 ℃ in ice bath, keeping.Reaction flask places outer the bath, and stirs this mixture down at 30 ℃.Stir and 30-40 ℃ under monoxone (31.1g) gradation is joined in this reactant mixture.After reinforced, under outside 30 ℃, bathing this mixture was further stirred 20 hours.This reactant mixture of cooling in the ice bath, and by under agitation to wherein adding acetic acid this mixture doorway that neutralizes, this pH value transfers to less than pH9).
(160ml) joins this mixture with water, and makes this mixture with respect to the water (Spectora that dialyses
/ Por 3 films, weight shutoff＜3500) and lyophilization obtain Sensor Chip CM 5 polyhydric alcohol (6.53g), it is an amorphous powder.
(5) Sensor Chip CM 5. polyhydric alcohol (1S; 9S)-1-(glycyl-glycyl-L-phenylalanyl-glycyl amino)-9-ethyl-5-fluoro-2; 3-dihydro-9-hydroxy-4-methyl-1H; 2H-benzo [de] pyrans also [3 '; 4 ': 6,7] indolizino [1,2-b] quinoline-10; 13 (9H, 15H)-preparation of diketone:
(40ml) places round-bottomed flask (capacity with water; In 5 minutes, stir simultaneously 100ml), under the room temperature to wherein adding Sensor Chip CM 5 polyhydric alcohol (1.0g).This mixture stir about 30 minutes is become clarification until this mixture.Stir down (1S; 9S)-1-(glycyl. glycyl-L-phenylalanyl-glycyl amino)-9-ethyl-5-fluoro-2; 3-dihydro-9-hydroxy-4-methyl-1,12H-benzo [de] pyrans also [3 ', 4 ': 6; 7] indolizino [1; 2b] and quinoline-10,13 (9H, 15H)-solution of diketone in dimethyl formamide (100mg/10ml) joins this mixture; and further stirred 10 minutes to wherein adding dimethyl formamide (15ml) and this mixture.Drip 2-ethyoxyl-1-ethoxy carbonyl-1 to this mixture under the room temperature, the solution of 2-dihydroquinoline (EEDQ) in dimethyl formamide (1.0g/10ml) stirs simultaneously, and this mixture further stirred 18 hours.This reactant mixture is dialysed with respect to water
Weight shutoff＜3500), and further pass through the cation exchange column purification
The MP-50 post, the Na-type, 30ml).Main distillate fraction is dialysed
Weight shutoff＜3500), and lyophilization obtains crude product, and it is pulverized with acetone, collect by filtering, and dilution obtains required product (904mg), and it is a buff powder.
Industrial applicibility
Pharmaceutical composition of the present invention can highly be accumulated in the position of the diffusible for example lymph node of cancer or liver, and the growth that acts on tumour cell does not affect normal cell simultaneously with suppressing, and therefore, pharmaceutical composition establishment of the present invention shifts, particularly suppress lymphatic metastasis or hepatic metastasis, perhaps prevent the recurrence of malignant tumour.
In addition, pharmaceutical composition of the present invention can not only also can shift its effect of the rear performance of beginning when shifting beginning. So, pharmaceutical composition of the present invention also establishment shift or the prevention topical therapeutic after Malignant Tumor Recurrence (for example, operation, radiotherapy, thermotherapy, cold therapy, laser calcination therapy etc.).
Claims (9)
1. polysaccharide derivates or its salt are used for suppressing to shift or prevent the application of the medicine of malignant tumor recurrence behind topical therapeutic in preparation, described polysaccharide derivates comprises having peptide of forming by aminoacid or by 2-8 identical or different aminoacid and the polysaccharide with bonded carboxyl of active substance of anti-tumor activity, and wherein said active substance with anti-tumor activity is the camptothecin derivative of formula (I):
R wherein
1Be that replace or unsubstituted low alkyl group, X
1Be formula :-NHR
2Group, R wherein
2Be that hydrogen atom or low alkyl group and Alk are the optional straight or branched C that contains oxygen atom in its chain
1-6Alkylidene, or the chemical compound of formula (II):
R wherein
2To R
6Two groups adjacent one another are are in conjunction with forming low-grade alkylidene, and a carbon atom of described low-grade alkylidene replaced by amino, and R
2To R
6Its excess-three group be hydrogen atom, low alkyl group or halogen atom.
2. the application of claim 1, wherein said topical therapeutic is operation, radiotherapy, thermotherapy, cryotherapy or laser calcination therapy.
3. the application of claim 1, the polysaccharide that wherein has carboxyl is carboxyl-C
1-4Alkyl glucosan or carboxyl-C
1-4Alkyl glucosan polyhydric alcohol.
4. the application of claim 1, the polysaccharide that wherein has carboxyl is carboxyl-C
1-4The alkyl glucosan.
5. the application of claim 3; wherein said peptide is to be selected from glycyl-glycyl-L-or D-phenylalanyl-glycine; glycyl-glycine; glycyl-glycyl-glycine; glycyl-glycyl-glycyl-glycine; glycyl-glycyl-glycyl-glycyl-glycine; L-or D-phenylalanyl-glycine; L-or D-tyrosyl--glycine; L-or D-leucyl--glycine, L-or D phenylalanyl-citrulline and L-or D-be valyl-a member of citrulline.
6. the application of claim 1; the polysaccharide that wherein has carboxyl is a carboxymethyl dextran resin; described active substance with anti-tumor activity is 10-(3 '-amino propoxyl group)-7-ethyl-(20S)-camptothecine, and described peptide is glycyl-glycyl-glycine.
7. the application of claim 1, the polysaccharide that wherein has carboxyl is carboxyl-C
1-4Alkyl glucosan polyhydric alcohol; described active substance with anti-tumor activity is (1S; 9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H, 12H-benzo [de]-pyrans also [3 '; 4 ': 6; 7] indole alkane [1,2-b] quinoline-10,13 (9H also; 15H)-diketone and described peptide are glycyl-glycyl-L-or D-phenylalanyl-glycine.
8. the application of claim 1, wherein said medicine are used to suppress malignant tumor and shift behind topical therapeutic.
9. the application of claim 1, wherein said medicine are used to prevent the malignant tumor recurrence behind topical therapeutic.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001249717 | 2001-08-21 | ||
| JP249717/2001 | 2001-08-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1545423A CN1545423A (en) | 2004-11-10 |
| CN100372570C true CN100372570C (en) | 2008-03-05 |
Family
ID=19078678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB028163176A Expired - Fee Related CN100372570C (en) | 2001-08-21 | 2002-08-16 | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1418947A1 (en) |
| KR (1) | KR20040027972A (en) |
| CN (1) | CN100372570C (en) |
| AR (1) | AR035137A1 (en) |
| AU (1) | AU2002328093B2 (en) |
| BR (1) | BR0212036A (en) |
| CA (1) | CA2457056C (en) |
| HU (1) | HUP0401351A3 (en) |
| IL (1) | IL160148A0 (en) |
| MX (1) | MXPA04001599A (en) |
| NO (1) | NO20041194L (en) |
| NZ (1) | NZ530947A (en) |
| PL (1) | PL368319A1 (en) |
| RU (1) | RU2275913C2 (en) |
| TW (1) | TWI313609B (en) |
| UA (1) | UA75450C2 (en) |
| WO (1) | WO2003015826A1 (en) |
| ZA (1) | ZA200400917B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306314A (en) * | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
| FR2914305B1 (en) | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | DEXTRAN FUNCTIONALIZED BY HYDROPHOBIC AMINO ACIDS |
| ES2672201T3 (en) | 2008-07-16 | 2018-06-13 | Children's Medical Center Corporation | Imitation device of organs with microchannels and methods of use |
| KR20190042747A (en) | 2011-06-02 | 2019-04-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Methods and uses for ex vivo tissue culture systems |
| PL221351B1 (en) | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Method for obtaining polysaccharide nanoparticles |
| RS60000B1 (en) | 2012-10-11 | 2020-04-30 | Daiichi Sankyo Co Ltd | Linkers for antibody-drug conjugates |
| ES2782248T3 (en) | 2012-10-19 | 2020-09-11 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate produced by binding through a linker having a hydrophilic structure |
| KR20230162159A (en) | 2014-01-31 | 2023-11-28 | 다이이찌 산쿄 가부시키가이샤 | Anti-her2 antibody-drug conjugate |
| WO2016178123A1 (en) | 2015-05-04 | 2016-11-10 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| US11173213B2 (en) | 2015-06-29 | 2021-11-16 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| WO2018110515A1 (en) | 2016-12-12 | 2018-06-21 | 第一三共株式会社 | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| JP6679762B2 (en) | 2017-01-17 | 2020-04-15 | 第一三共株式会社 | Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate |
| TW202330036A (en) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | Manufacturing method of antibody-drug conjugates |
| CN117865839A (en) | 2017-08-31 | 2024-04-12 | 第一三共株式会社 | New method for preparing antibody-drug conjugate |
| BR112020003646A2 (en) | 2017-08-31 | 2020-09-01 | Daiichi Sankyo Company, Limited | crystals, methods for producing crystals and an antibody-drug conjugate, and, salt. |
| KR20210010565A (en) | 2018-05-18 | 2021-01-27 | 글리코토페 게엠베하 | Anti-MUC1 antibody |
| CN109481691A (en) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | Gemcitabine-carboxymethyl polysaccharide conjugate, preparation method and its usage |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0640622A1 (en) * | 1993-02-26 | 1995-03-01 | Drug Delivery System Institute, Ltd. | Polysaccharide derivative and drug carrier |
| CN1145365A (en) * | 1995-08-02 | 1997-03-19 | 田边制药株式会社 | Camptothecin derivatives |
| CN1158344A (en) * | 1996-12-31 | 1997-09-03 | 中国科学院感光化学研究所 | Low contract photo-solidification cladding material, its prepn. method and use |
| EP0916348A1 (en) * | 1996-06-06 | 1999-05-19 | Daiichi Pharmaceutical Co., Ltd. | Drug complexes |
| EP1080732A1 (en) * | 1998-05-22 | 2001-03-07 | Daiichi Pharmaceutical Co., Ltd. | Drug composites |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2192725C (en) * | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| DE69734709D1 (en) * | 1996-04-15 | 2005-12-29 | Asahi Chemical Ind | MEDICINAL COMPLEXES CONTAINING TAXAN COMPOUNDS OR STEROIDS |
-
2002
- 2002-08-14 TW TW091118260A patent/TWI313609B/en not_active IP Right Cessation
- 2002-08-15 AR ARP020103077A patent/AR035137A1/en unknown
- 2002-08-16 EP EP02762786A patent/EP1418947A1/en not_active Withdrawn
- 2002-08-16 IL IL16014802A patent/IL160148A0/en unknown
- 2002-08-16 NZ NZ530947A patent/NZ530947A/en not_active IP Right Cessation
- 2002-08-16 HU HU0401351A patent/HUP0401351A3/en unknown
- 2002-08-16 BR BR0212036-4A patent/BR0212036A/en not_active IP Right Cessation
- 2002-08-16 CA CA002457056A patent/CA2457056C/en not_active Expired - Fee Related
- 2002-08-16 CN CNB028163176A patent/CN100372570C/en not_active Expired - Fee Related
- 2002-08-16 AU AU2002328093A patent/AU2002328093B2/en not_active Ceased
- 2002-08-16 MX MXPA04001599A patent/MXPA04001599A/en unknown
- 2002-08-16 PL PL02368319A patent/PL368319A1/en not_active Application Discontinuation
- 2002-08-16 RU RU2004108141/15A patent/RU2275913C2/en not_active IP Right Cessation
- 2002-08-16 WO PCT/JP2002/008309 patent/WO2003015826A1/en active IP Right Grant
- 2002-08-16 UA UA2004032071A patent/UA75450C2/en unknown
- 2002-08-16 KR KR10-2004-7002566A patent/KR20040027972A/en not_active Application Discontinuation
-
2004
- 2004-02-04 ZA ZA200400917A patent/ZA200400917B/en unknown
- 2004-03-19 NO NO20041194A patent/NO20041194L/en not_active Application Discontinuation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0640622A1 (en) * | 1993-02-26 | 1995-03-01 | Drug Delivery System Institute, Ltd. | Polysaccharide derivative and drug carrier |
| CN1145365A (en) * | 1995-08-02 | 1997-03-19 | 田边制药株式会社 | Camptothecin derivatives |
| EP0916348A1 (en) * | 1996-06-06 | 1999-05-19 | Daiichi Pharmaceutical Co., Ltd. | Drug complexes |
| CN1158344A (en) * | 1996-12-31 | 1997-09-03 | 中国科学院感光化学研究所 | Low contract photo-solidification cladding material, its prepn. method and use |
| EP1080732A1 (en) * | 1998-05-22 | 2001-03-07 | Daiichi Pharmaceutical Co., Ltd. | Drug composites |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI313609B (en) | 2009-08-21 |
| NZ530947A (en) | 2006-04-28 |
| HUP0401351A3 (en) | 2011-02-28 |
| MXPA04001599A (en) | 2004-07-08 |
| RU2275913C2 (en) | 2006-05-10 |
| ZA200400917B (en) | 2004-08-25 |
| CA2457056C (en) | 2008-07-22 |
| UA75450C2 (en) | 2006-04-17 |
| HUP0401351A2 (en) | 2004-12-28 |
| CA2457056A1 (en) | 2003-02-27 |
| PL368319A1 (en) | 2005-03-21 |
| RU2004108141A (en) | 2005-04-20 |
| WO2003015826A1 (en) | 2003-02-27 |
| AU2002328093B2 (en) | 2005-05-05 |
| AR035137A1 (en) | 2004-04-14 |
| CN1545423A (en) | 2004-11-10 |
| KR20040027972A (en) | 2004-04-01 |
| NO20041194L (en) | 2004-03-19 |
| EP1418947A1 (en) | 2004-05-19 |
| IL160148A0 (en) | 2004-07-25 |
| BR0212036A (en) | 2004-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100372570C (en) | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor | |
| BG108274A (en) | Conjugate of hydroxyalkyl starch and an active agent | |
| WO1997046260A1 (en) | Drug complexes | |
| CN106170303A (en) | By the prodrug of caspase activation | |
| US20100266590A1 (en) | Combination therapy | |
| JPH08504217A (en) | Polymer bound camptothecin derivative | |
| JP6223995B2 (en) | High molecular weight compound combining camptothecins and anticancer effect enhancer and use thereof | |
| KR20160064726A (en) | Conjugate of Cell Penetrating Peptides-Anti-cancer Agent and Composition Comprising the Same | |
| CN115725586A (en) | Aptamer modified structure of targeting PTK7, coupled drug thereof, preparation method and application | |
| AU2002328093A1 (en) | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor | |
| JPH1192405A (en) | Medicinal complex | |
| JP2003509372A (en) | Formulations for parenteral use of estramustine phosphate and amino acids | |
| JPH02500368A (en) | How to inhibit tumors in warm-blooded animals | |
| US20060052288A1 (en) | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | |
| KR20210104463A (en) | Novel use of chemotherapeutic prodrug conjugate | |
| EP1112066B1 (en) | Use of methoxymorpholino doxorubicin for the treatment of a liver tumor | |
| WO2009096245A9 (en) | Pharmaceutical composition and combined agent | |
| JP5341314B2 (en) | Drug delivery system | |
| WO2021229832A1 (en) | Water-soluble polymeric derivative of venetoclax | |
| AU2013226944B2 (en) | Inhibitory agent for body cavity fluid accumulation | |
| KR102346268B1 (en) | Complex comprising oral anticancer prodrugs, their preperation methods and applications | |
| WO2001026677A1 (en) | Interferon complex and medicinal use thereof | |
| US20120053144A1 (en) | Cobalamin Taxane Bioconjugates For Treating Eye Disease | |
| JP2003137818A (en) | Composition for metastasis control or recurrence prevention of carcinoma | |
| US20240207301A1 (en) | Pharmaceutical composition and anti-tumor agent for tumor having decreased function of at least one of bap1 or pbrm1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080305 Termination date: 20100816 |